DMAC vs ARCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARCT counters with relative strength in Valuation. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ARCT at 2.5x Forward P/E and -311.2% operating margin (+6.7% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against ARCT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | ARCT Revenue | DMAC Op. Margin | ARCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $20M | -1352.2% | -138.5% | ARCT |
| FY2019 | N/A | $20M | N/A | -122.7% | ARCT |
| FY2020 | N/A | $10M | N/A | -749.8% | ARCT |
| FY2021 | N/A | $10M | N/A | -1641.3% | ARCT |
| FY2022 | N/A | $210M | N/A | 5.9% | ARCT |
| FY2023 | N/A | $170M | N/A | -46.9% | ARCT |
| FY2024 | N/A | $150M | N/A | -62.8% | ARCT |
| FY2025 | N/A | $80M | N/A | -93.0% | ARCT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | ARCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $241.0M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | N/M | 2.5x | Lower Multiple | ARCT |
| Forward P/E Ratio Valuation | N/M | 2.5x | Lower Multiple | ARCT |
| Revenue Growth (YoY) Growth | +0.0% | +6.7% | Higher Growth | ARCT |
| Operating Margin (TTM) Profitability | 0.0% | -311.2% | Higher Margin | DMAC |
| Net Profit Margin Profitability | 0.0% | -285.9% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -114.6% | -44.4% | Higher ROE | ARCT |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 25% ($6โ$18) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 2.03ฮฒ ยท 127% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 57.7 / 100 (HOLD) | Higher Composite | ARCT |